Special Issue "Design, Synthesis and Biological Evaluation with Potential Anti-inflammatory Activity"
Deadline for manuscript submissions: 26 January 2024 | Viewed by 1388
Interests: synthesis; 1,2-benzothiazine; oxicams; anti-inflammatory; chemoprevention; cancer
Interests: molecular modeling; anti-inflammatory drugs; drug design
Special Issues, Collections and Topics in MDPI journals
Inflammation is a kind of defensive body reaction in response to damaging factors. Cells of the immune system, connective tissue cells, some blood proteins, and blood vessels are involved in the inflammatory reaction. The purpose of inflammation is to limit the harmful factor, neutralize it and repair damaged tissues. Sometimes, the immune response is inappropriately intensified in relation to the damaging stimulus or is directed against healthy tissues.
Many studies have shown that the inflammatory process is involved in the initiation and progression of many diseases, such as asthma, rheumatoid arthritis, cardiovascular disorders, diabetes, Crohn's disease, multiple sclerosis, neurogenerative disorders such as Alzheimer's disease, and even cancer. Inflammatory diseases are a widespread medical, social, and economic burden, and their pharmacotherapy is still an unresolved problem. Therefore, there is a great and urgent need to develop anti-inflammatory drugs with new mechanisms of action.
Research in recent years has shown that very different signaling pathways are associated with the initiation and progression of inflammation. The classical inflammatory pathways are IL-6/JAK/STAT3, p38 MAPK, and PI3K, and non-classical ones include Hippo. Recently, the Hippo pathway has been linked to various inflammatory modulators such as TNF-α, IL-6, COX-2, HIF-1α, AP-1, JAK, and STAT. In addition to searching for compounds with innovative anti-inflammatory mechanisms, it is also worth continuing research on compounds with anti-inflammatory effects that are associated with blocking COX/LOX enzymes and multi-target drug design.
The purpose of this Special Issue is to gather original and review articles presenting data on the design, synthesis, pharmacological research, and molecular modeling of new compounds with potential anti-inflammatory activity.
Dr. Berenika M. Szczȩśniak-Siȩga
Dr. Żaneta Czyżnikowska
Dr. Aleksandra Redzicka
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer's disease